

Axel Grothey

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6865314/axel-grothey-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

246
papers

20,392
citations

59
h-index

141
g-index

273
ext. papers

24,446
ext. citations

7.3
avg, IF

6.58
L-index

#	Paper	IF	Citations
246	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013 , 381, 303-12	4.0	1783
245	Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3219-26	2.2	1063
244	Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3677-83	2.2	955
243	Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2903-9	2.2	942
242	Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1209-14	2.2	888
241	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-11	19.1888	0
240	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet, The</i> , 2017 , 390, 1473-83	21.7	568
239	Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). <i>Journal of Clinical Oncology</i> , 2008 , 26, 5326-34	2.2	561
238	Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8664-70	2.2	509
237	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 370-398	7.3	485
236	Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 1632-1643	59.2	481
235	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 359-369	7.3	433
234	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 1177-1188	59.2	429
233	Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 874-901	7.3	429
232	Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 872-7	2.2	400
231	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020 , 25, e936-e945	5.7	356
230	Cyclooxygenase-2: a novel target for cancer chemotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001 , 127, 411-7	4.9	339

229	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 1383-93	27.4	330
228	Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 507-18	19.4	297
227	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2019 , 5, 1008-1019	13.4	288
226	Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. <i>Annals of Surgical Oncology</i> , 2006 , 13, 1261-8	3.1	264
225	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology, The</i> , 2016 , 17, 1709-1719	21.7	258
224	Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. <i>Oncologist</i> , 2009 , 14, 862-70	5.7	256
223	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology, The</i> , 2015 , 16, 937-48	21.7	240
222	Biomarkers and surrogate end points--the challenge of statistical validation. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 309-17	19.4	240
221	Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4217-23	2.2	235
220	The continuum of care: a paradigm for the management of metastatic colorectal cancer. <i>Oncologist</i> , 2007 , 12, 38-50	5.7	190
219	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3227-33	2.2	182
218	BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2624-2630	2.2	176
217	Drug rechallenge and treatment beyond progression--implications for drug resistance. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 571-87	19.4	174
216	Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). <i>Journal of Clinical Oncology</i> , 2015 , 33, 3416-22	2.2	167
215	A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. <i>Journal of Pain and Symptom Management</i> , 2013 , 45, 811-21	4.8	165
214	Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). <i>Journal of Clinical Oncology</i> , 2014 , 32, 997-1005	2.2	156
213	Rectal Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 719-28; quiz 728	7.3	154
212	Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. <i>Journal of Clinical Oncology</i> , 2008 , 26, 183-9	2.2	153

211	5-fluorouracil and cardiotoxicity: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 17588359-18780140		
210	Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4853-5	2.2	135
209	Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1948-55	2.2	125
208	Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2006 , 6, 29-31	3.8	123
207	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1460-1469	2.2	114
206	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018 , 16, 805-812	6.6	114
205	Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. <i>Clinical Cancer Research</i> , 2012 , 18, 546-54	12.9	111
204	Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	109
203	Integrating biomarkers in clinical trials. <i>Expert Review of Molecular Diagnostics</i> , 2011 , 11, 171-82	3.8	104
202	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , 2019 , 20, 1070-1082	21.7	101
201	C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. <i>Oncogene</i> , 2000 , 19, 4864-75	9.2	90
200	Cisplatin resistance and oncogenes--a review. <i>Anti-Cancer Drugs</i> , 2000 , 11, 225-36	2.4	89
199	Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. <i>Cancer Research</i> , 2003 , 63, 513-21	10.1	89
198	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2112-19	1	82
197	Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. <i>Oncologist</i> , 2012 , 17, 1486-95	5.7	82
196	A review of oxaliplatin and its clinical use in colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2159-70	4	79
195	Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. <i>Drugs</i> , 2017 , 77, 1091-1103	12.1	78
194	Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. <i>Investigational New Drugs</i> , 2015 , 33, 740-50	4.3	73

193	Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1936-41	2.2	72
192	Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. <i>Journal of Clinical Oncology</i> , 2015 , 33, 22-8	2.2	69
191	Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. <i>Lancet Oncology, The</i> , 2016 , 17, 663-70	21.7	69
190	Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 852-871	7.3	63
189	Randomized phase II trials: inevitable or inadvisable?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2641-7	2.2	61
188	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016 , 1, e000097	6	59
187	Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2008 , 14, 170-7	2.2	57
186	Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3656-63	2.2	56
185	A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes. <i>Retina</i> , 2012 , 32, 1959-66 ^{3.6}	3.6	56
184	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2020 , 21, 1620-1629	21.7	55
183	Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. <i>Oncologist</i> , 2014 , 19, 669-80	5.7	53
182	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 779-789	21.7	53
181	The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	52
180	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. <i>Oncologist</i> , 2019 , 24, 185-192	5.7	52
179	Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). <i>Supportive Care in Cancer</i> , 2016 , 24, 5059-5068	3.9	50
178	Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. <i>Journal of Clinical Oncology</i> , 2010 , 28, 460-5	2.2	49
177	ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	48
176	Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. <i>European Journal of Haematology</i> , 2005 , 74, 263-6	3.8	45

175	Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. <i>BMC Cancer</i> , 2016 , 16, 467-48	4.8	43
174	Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 7492-7501	12.9	42
173	New chemotherapy approaches in colorectal cancer. <i>Current Opinion in Oncology</i> , 2001 , 13, 275-86	4.2	42
172	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2015 , 41, 653-9	14.4	41
171	Adolescent and young adult colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 1219-25	7.3	39
170	Clinical trial designs for prospective validation of biomarkers. <i>Molecular Diagnosis and Therapy</i> , 2005 , 5, 317-25		39
169	Phase I trial of a pathotropic retroviral vector expressing a cytotoxic cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. <i>Molecular Therapy</i> , 2008 , 16, 979-84	11.7	37
168	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4000-4000	2.2	37
167	MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. <i>Supportive Care in Cancer</i> , 2016 , 24, 1071-8	3.9	36
166	Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 100-9	3.8	36
165	Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 726-34	2.6	36
164	Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. <i>Journal of Clinical Oncology</i> , 2014 , 32, 841-50	2.2	35
163	Colorectal cancer in 2014: progress in defining first-line and maintenance therapies. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 73-4	19.4	35
162	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020 , 5, e000682	6	34
161	Curable metastatic colorectal cancer. <i>Current Oncology Reports</i> , 2011 , 13, 168-76	6.3	34
160	Treatment options for advanced pancreatic cancer: a review. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1327-36	3.5	32
159	Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. <i>International Journal of Cancer</i> , 2020 , 147, 2948-2956	7.5	32
158	Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). <i>Cancer</i> , 2012 , 118, 1083-90	6.4	29

157	Targeting colorectal cancer with human anti-EGFR monoclonal antibodies: focus on panitumumab. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 223-8	4.4	29
156	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1929-1937	2.2	28
155	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017 , 16, 124-128	3.8	28
154	Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. <i>Oncologist</i> , 2012 , 17, 725-31	5.7	28
153	Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2007 , 110, 670-7	6.4	27
152	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 1306-1314	5.7	27
151	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021 , 39, 642-651	2.2	27
150	Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 60-4	3.8	26
149	Impact of Metastasectomy in the Multimodality Approach for V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. <i>Oncologist</i> , 2018 , 23, 128-134	5.7	25
148	Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2012 , 4, 301-19	5.4	25
147	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020 , 86, 101993	14.4	24
146	Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. <i>Oncologist</i> , 2018 , 23, 1083-1091	5.7	24
145	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). <i>Oncologist</i> , 2016 , 21, 1509-1521	5.7	24
144	Chemotherapy Maintenance. <i>Cancer Journal (Sudbury, Mass)</i> , 2016 , 22, 199-204	2.2	24
143	Antiangiogenesis agents in colorectal cancer. <i>Current Opinion in Oncology</i> , 2010 , 22, 374-80	4.2	24
142	N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. <i>Clinical Colorectal Cancer</i> , 2005 , 5, 211-3	3.8	24
141	Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer. <i>Oncology</i> , 2010 , 79, 389-99	3.6	23
140	Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. <i>Clinical Colorectal Cancer</i> , 2004 , 4, 46-50	3.8	23

139	Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4004-4004	2.2	23
138	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1182-9	2.2	22
137	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 106-126	5.4	22
136	Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 313-4	19.4	22
135	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4001-4001	2.2	22
134	Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. <i>Cancer</i> , 2011 , 117, 4155-65	6.4	21
133	Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 52-57	3.8	21
132	Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. <i>Seminars in Oncology</i> , 2010 , 37, 39-46	5.5	20
131	FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3311-3	2.2	20
130	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018 , 100, 35-45	7.5	20
129	Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. <i>Frontiers in Oncology</i> , 2019 , 9, 76	5.3	19
128	Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. <i>Clinical Colorectal Cancer</i> , 2006 , 6, 261-4	3.8	19
127	Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients. <i>Drugs</i> , 2018 , 78, 737-745	12.1	17
126	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	16
125	Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. <i>Supportive Care in Cancer</i> , 2005 , 13, 26-31	3.9	16
124	Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 961-969	3.5	16
123	First- and second-line therapy of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 921-30	3.5	15
122	KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. <i>Oncologist</i> , 2011 , 16, 1061-8	5.7	14

121	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1451-1455	8.7	14
120	Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 514-7	0.6	14
119	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. <i>ESMO Open</i> , 2018 , 3, e000347	6	13
118	The search for treatments to reduce chemotherapy-induced peripheral neuropathy. <i>Journal of Clinical Investigation</i> , 2014 , 124, 72-4	15.9	13
117	Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. <i>Oncologist</i> , 2011 , 16, 859-67	5.7	13
116	Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2004 , 4 Suppl 1, S37-42	3.8	13
115	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, 404-413	5.7	13
114	Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. <i>Seminars in Oncology</i> , 2006 , 33, S41-9	5.5	12
113	New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference. <i>Clinical Cancer Research</i> , 2007 , 13, 6853s-6s	12.9	12
112	Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas. <i>Clinical and Experimental Metastasis</i> , 1999 , 17, 171-6	4.7	12
111	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020 , 20, 101-109	3.8	12
110	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1277-1286	27.4	12
109	When less is more: maintenance therapy in colorectal cancer. <i>Lancet, The</i> , 2015 , 385, 1808-10	40	11
108	MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1197-1204	4.9	11
107	Molecular characteristics of and mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020 , 5, e000942	6	11
106	Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. <i>Journal of the American Society of Echocardiography</i> , 2019 , 32, 267-276	5.8	11
105	Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. <i>Cancer Management and Research</i> , 2017 , 9, 149-158	3.6	10
104	Regorafenib in the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 137-454		10

103	Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1097-101	7.3	10
102	A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001 , 127, 96-100	4.9	10
101	Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. <i>Anti-Cancer Drugs</i> , 1998 , 9, 405-9	2.4	10
100	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 316-325	12.9	10
99	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>European Journal of Cancer</i> , 2018 , 103, 205-213	7.5	9
98	Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 611-615	7.3	9
97	A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience. <i>Oncologist</i> , 2018 , 23, 679-685	5.7	8
96	Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCTG N0949 (alliance). <i>Journal of Geriatric Oncology</i> , 2018 , 9, 24-31	3.6	8
95	VEGF inhibition beyond tumour progression. <i>Lancet Oncology, The</i> , 2013 , 14, 2-3	21.7	8
94	-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020 , 12,	6.6	7
93	Medical treatment of advanced colorectal cancer in 2009. <i>Therapeutic Advances in Medical Oncology</i> , 2009 , 1, 55-68	5.4	7
92	A new prognostic and predictive tool for shared decision making in stage III colon cancer. <i>European Journal of Cancer</i> , 2020 , 138, 182-188	7.5	7
91	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1174-1183	12.9	7
90	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as	7.1	6
89	Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920910913	5.4	6
88	EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?. <i>Lancet Oncology, The</i> , 2020 , 21, 324-326	21.7	6
87	Regorafenib for metastatic colorectal cancer - AuthorsPreply. <i>Lancet, The</i> , 2013 , 381, 1538-9	4.0	6
86	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. <i>OncoTargets and Therapy</i> , 2015 , 8, 2949-57	4.4	6

85	Does stage II colorectal cancer need to be redefined?. <i>Clinical Cancer Research</i> , 2011 , 17, 3053-5	12.9	6
84	The role of chemotherapy in managing patients with resectable liver metastases. <i>Cancer Journal (Sudbury, Mass)</i> , 2010 , 16, 125-31	2.2	6
83	Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. <i>Statistical Methods in Medical Research</i> , 2008 , 17, 529-35	2.3	6
82	Biological therapy and other novel therapies in early-stage disease: are they appropriate?. <i>Clinical Cancer Research</i> , 2007 , 13, 6909s-12s	12.9	6
81	Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?. <i>Clinical Colorectal Cancer</i> , 2006 , 6, 196-201	3.8	6
80	Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e183-e187	3.8	6
79	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 933-946	18.8	6
78	Regorafenib in metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2012 , 10, 324-5	0.6	6
77	Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. <i>Supportive Care in Cancer</i> , 2019 , 27, 3869-3875	3.9	5
76	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , 2020 , 25, e1426-e1427	5.7	5
75	A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer. <i>Nature Clinical Practice Oncology</i> , 2009 , 6, 10-1		5
74	Adjuvant therapy for colon cancer: learning from the past to inform the future. <i>Annals of Surgical Oncology</i> , 2010 , 17, 947-9	3.1	5
73	Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. <i>Oncology Research and Treatment</i> , 2005 , 28, 88-92	2.8	5
72	Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients 2015 , 2,		5
71	Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. <i>Case Reports in Oncological Medicine</i> , 2015 , 2015, 420159	0.9	4
70	The role of regorafenib in metastatic colorectal cancer. <i>Lancet Oncology</i> , 2015 , 16, 596-7	21.7	4
69	Should oncologists routinely discuss fertility preservation with cancer patients of childbearing age?. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 6-7	6.4	4
68	North Central Cancer Treatment Group--achievements and perspectives. <i>Seminars in Oncology</i> , 2008 , 35, 530-44	5.5	4

67	Developments in combination chemotherapy for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 627-37	3.5	4
66	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy + biologic: Findings from 9,092 pts in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3535-3535	2.2	4
65	Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3599-3599	2.2	4
64	Clinical and Functional Characterization of Atypical / Mutations in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 4587-4598	12.9	4
63	Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 28, 1417-1427	3.1	4
62	Evidence in Favor of Standard Surgical Treatment for Rectal Cancer. <i>JAMA Oncology</i> , 2017 , 3, 885-886	13.4	3
61	Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. <i>Hpb</i> , 2013 , 15, 116-8	3.8	3
60	Reply to D.J. Stewart. <i>Journal of Clinical Oncology</i> , 2010 , 28, e652-e653	2.2	3
59	Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. <i>Anti-Cancer Drugs</i> , 1999 , 10, 545-9	2.4	3
58	Metastatic extramammary Paget's disease responding to weekly paclitaxel. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	3
57	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2020 , 17, 100492	1.8	3
56	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. <i>Oncologist</i> , 2021 , 26, 651-659	5.7	3
55	Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3513-3513	2.2	3
54	Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211024460	4.7	3
53	Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer. <i>JCO Oncology Practice</i> , 2021 , 17, 383-402	2.3	3
52	Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers. <i>Lancet Oncology</i> , 2017 , 18, 1427-1428	21.7	2
51	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D levels and survival among patients with metastatic colorectal cancer. <i>Cancer Causes and Control</i> , 2019 , 30, 757-765	2.8	2
50	New Adjuvant Trial Designs in Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 326-334	1	2

49	Optimizing systemic therapy selection in metastatic colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 682-5	7.3	2
48	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211020547	5.4	2
47	BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. <i>BMJ Open</i> , 2021 , 11, e047833		2
46	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100181	3.6	2
45	Landscape of , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in -Mutated Cancers.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100245	3.6	2
44	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.. <i>ESMO Open</i> , 2021 , 6, 100328	6	2
43	Distinctive Tumor Biology of MSI-High Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 281-287	1	1
42	Adverse event development in clinical oncology trials - AuthorsPreply. <i>Lancet Oncology, The</i> , 2016 , 17, e264-e265	21.7	1
41	Reply to S.A. Kesikli et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2288-2289	2.2	1
40	Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 22-3		1
39	Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 612-612	2.2	1
38	Minimally Invasive Surgery ¶Where are We? is there a Role for TEM?73-88		1
37	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021 , 5, 95	9.8	1
36	Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers. <i>Current Colorectal Cancer Reports</i> , 2021 , 17, 55-68	1	1
35	Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. <i>Cancer Management and Research</i> , 2021 , 13, 5523-5533	3.6	1
34	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. <i>Investigational New Drugs</i> , 2016 , 34, 96-103	4.3	1
33	Therapy: Colorectal cancer: how to teach an old drug new tricks. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 384-5	24.2	1
32	Does Lifestyle Cause Colorectal Cancer?1-13		1

31	The Role of the Colorectal Nurse Specialist in the Management of Colorectal Cancer	153-166	1
30	Risk assessment in stage II colon cancer: to treat or not to treat?. <i>Oncology</i> , 2010 , 24, 1-2		1.8 1
29	Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the Way. <i>JAMA Network Open</i> , 2020 , 3, e2030508		10.4 0
28	Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3583-3583		2.2 0
27	Microsatellite Stable Colorectal Liver Metastases-Understanding the Mechanisms of Immune Resistance. <i>JAMA Network Open</i> , 2021 , 4, e2119025		10.4 0
26	Optimal Treatment Strategies for Localized and Advanced Microsatellite Instability-High Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 36-41		1
25	S-1 in colorectal cancer: a new standard of care?. <i>Lancet Oncology, The</i> , 2012 , 13, 1068-70		21.7
24	Recent developments in therapy for gastrointestinal cancers. <i>Community Oncology</i> , 2011 , 8, 4-8		
23	Reduced Chemotherapy Duration: A Good Idea?. <i>Current Colorectal Cancer Reports</i> , 2011 , 7, 241-245		1
22	Reply to F. Montagnani et al. <i>Journal of Clinical Oncology</i> , 2009 , 27, e134-e135		2.2
21	Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial. <i>Current Colorectal Cancer Reports</i> , 2009 , 5, 65-66		1
20	Reply to A. Chan et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e490-e491		2.2
19	Reply to S.B. Park et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e555-e556		2.2
18	Reply to M. Mandal et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1895-1895		2.2
17	Establishing a standard of care for small bowel adenocarcinomas: challenges and lessons learned. <i>Oncologist</i> , 2012 , 17, 1133-4		5.7
16	Strategies for Managing Chemotherapy-Induced Sensory Neuropathy. <i>Current Colorectal Cancer Reports</i> , 2010 , 6, 126-132		1
15	Should bevacizumab be continued beyond progression in colorectal cancer?. <i>Current Colorectal Cancer Reports</i> , 2008 , 4, 139-143		1
14	Improving the Odds for a Patient With Potentially Curable Stage IV Colorectal Cancer: A Question of Chemosensitivity. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 258-60		

- 13 Waiting in line for cancer treatments?. *Gastrointestinal Cancer Research: GCR*, **2011**, 4, 147-9
- 12 Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). *International Journal of Statistics in Medical Research*, **2018**, 7, 137-146 3
- 11 Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. *Oncologist*, **2021**, 26, 610-618 5-7
- 10 Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.. *Journal of Clinical Oncology*, **2021**, 39, 3517-3517 2.2
- 9 The Role of the Multidisciplinary Team in the Management of Colorectal Cancer167-177
- 8 Follow-Up after Colorectal Cancer Resection: Is it Worth While?178-194
- 7 Surgery for Metastatic Disease in Colorectal Cancer213-231
- 6 Palliative Care of the Colorectal Cancer Patient232-250
- 5 Future Directions in the Oncological Treatment of Colorectal Cancer251-270
- 4 MRI-Directed Rectal Cancer Surgery46-59
- 3 What is the Best Strategy for the Management of Hereditary Colorectal Cancer?89-111
- 2 Adjuvant Radiotherapy and Chemoradiotherapy in the Treatment of Rectal Cancer112-132
- 1 Introduction to special issue on biomarker-based clinical trial designs in oncology. *Chinese Clinical Oncology*, **2015**, 4, 28 2.3